Table 4.
Effect of AZD1981 50–1,000 mg bid vs placebo on the change in FEV1 measured in the clinic and ACQ-5 in all patients, atopic patients, and nonatopic patients from study 2
| Population | Variable | AZD1981 vs placebo (mean difference [95% CI])
|
||
|---|---|---|---|---|
| 50 mg bid | 400 mg bid | 1,000 mg bid | ||
| All patients | FEV1 (L) | 0.10 (−0.042, 0.25) | 0.18 (0.0036, 0.33) | 0.095 (−0.050, 0.24) |
| ACQ-5 | −0.28 (−0.51, −0.047) | −0.28 (−0.51, −0.042) | −0.30 (−0.53, −0.060) | |
| Atopic patients | FEV1 (L) | 0.13 (−0.043, 0.30) | 0.18 (0.014, 0.35) | 0.17 (−0.006, 0.34) |
| ACQ-5 | −0.42 (−0.69, −0.15) | −0.40 (−0.67, −0.13) | −0.38 (−0.67, −0.096) | |
| Nonatopic patients | FEV1 (L) | 0.035 (−0.25, 0.32) | 0.21 (−0.089, 0.51) | −0.039 (−0.31, 0.23) |
| ACQ-5 | 0.095 (−0.36, 0.55) | 0.10 (−0.38, 0.58) | −0.031 (−0.47, 0.40) | |
Note: Study 2 was a 4-week, randomized, placebo-controlled dose-range finding study that assessed the efficacy and tolerability of AZD1981 in patients with asthma not controlled on ICS.
Abbreviations: ACQ, Asthma Control Questionnaire; bid, twice daily; CI, confidence interval; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.